Aggressive cancers like pancreatic cancer present formidable obstacles: dense tumour microenvironments that block immune cells and chemotherapy, and oncogenic pathways that evade single-target therapies. Verastem Oncology’s Chief Scientific Officer Dr. Jonathan Pachter, is confronting these challenges with a multifaceted strategy that targets both the tumour microenvironment and cancer-driving pathways like RAS/MAPK. In an engaging interview, … The Fight Against Hard-to-Treat Cancers : Bold Bets on a Multifaceted Approach Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.